Hind Karimi1, Latifa En-Nanai2, Amal Oudghiri3, Imane Chaoui4, Amin Laglaoui5, Jamal Eddine Bourkadi6, Mohammed El Mzibri7, Mohammed Abid2. 1. Service de recherche, Laboratoire de biologie moléculaire, Institut Pasteur du Maroc, 90 000 Tangier, Morocco; Equipe de Recherche Biotechnologie et Génie des Biomolécules, FST de Tanger, 90 000 Tangier, Morocco. 2. Service de recherche, Laboratoire de biologie moléculaire, Institut Pasteur du Maroc, 90 000 Tangier, Morocco. 3. Equipe de Recherche Biotechnologie et Génie des Biomolécules, FST de Tanger, 90 000 Tangier, Morocco; Unité de Biologie et Recherche Médicale, Centre National de l'Energie, des Sciences et Techniques Nucléaires, B.P. 1382 R.P. 10001 Rabat, Morocco. 4. Unité de Biologie et Recherche Médicale, Centre National de l'Energie, des Sciences et Techniques Nucléaires, B.P. 1382 R.P. 10001 Rabat, Morocco. 5. Equipe de Recherche Biotechnologie et Génie des Biomolécules, FST de Tanger, 90 000 Tangier, Morocco. 6. Service de Pneumo-Phtisiologie, Hôpital Moulay Youssef, CHU Ibn Sina, 10 000 Rabat, Morocco. 7. Unité de Biologie et Recherche Médicale, Centre National de l'Energie, des Sciences et Techniques Nucléaires, B.P. 1382 R.P. 10001 Rabat, Morocco. Electronic address: elmzibri@cnesten.org.ma.
Abstract
OBJECTIVES: In Morocco, tuberculosis (TB) is a major public health problem with high morbidity and mortality. The main problem faced by the national TB programme is the high rate of drug-resistant (DR), particularly multi-drug resistant (MDR) strains. Diagnosis of DR-TB is mainly performed by conventional techniques that are time consuming with limited efficacy. In 2014, the GenoType® MTBDRplus assay was introduced in Morocco for drug susceptibility testing (DST). In this regard, the present study was planned to assess the diagnostic accuracy of the GenoType® MTBDRplus assay. METHODS: A total of 70 samples from suspected TB cases in Tangier (Morocco) were analysed by conventional DST and GenoType® MTBDRplus assay. RESULTS: Among the 70 samples, 37.1% were MDR, whereas monoresistance to isoniazid (INH) and rifampicin (RIF) was detected in 186% and 17.1% of strains, respectively, by DST. Using the GenoType® MTBDRplus approach, 12 isolates (17.1%) were identified as INH monoresistant, 9 (12.9%) as RIF monoresistant and 26 (37.1%) as MDR. rpoB531 and katG315 mutations were the most common mutations associated with resistance to RIF and INH, respectively. Significantly, all phenotypically MDR strains were also MDR by GenoType® MTBDRplus. The sensitivity of GenoType® MTBDRplus was 92.1% for RIF resistance and 97.4% for INH resistance, whereas the specificity was 100% for the two tested drugs. CONCLUSIONS: GenoType® MTBDRplus assay is a rapid, reliable and accurate tool for the detection of DR-TB in clinical specimens. Its routine use will be of a great interest to prevent the dissemination of DR-TB in the community.
OBJECTIVES: In Morocco, tuberculosis (TB) is a major public health problem with high morbidity and mortality. The main problem faced by the national TB programme is the high rate of drug-resistant (DR), particularly multi-drug resistant (MDR) strains. Diagnosis of DR-TB is mainly performed by conventional techniques that are time consuming with limited efficacy. In 2014, the GenoType® MTBDRplus assay was introduced in Morocco for drug susceptibility testing (DST). In this regard, the present study was planned to assess the diagnostic accuracy of the GenoType® MTBDRplus assay. METHODS: A total of 70 samples from suspected TB cases in Tangier (Morocco) were analysed by conventional DST and GenoType® MTBDRplus assay. RESULTS: Among the 70 samples, 37.1% were MDR, whereas monoresistance to isoniazid (INH) and rifampicin (RIF) was detected in 186% and 17.1% of strains, respectively, by DST. Using the GenoType® MTBDRplus approach, 12 isolates (17.1%) were identified as INH monoresistant, 9 (12.9%) as RIF monoresistant and 26 (37.1%) as MDR. rpoB531 and katG315 mutations were the most common mutations associated with resistance to RIF and INH, respectively. Significantly, all phenotypically MDR strains were also MDR by GenoType® MTBDRplus. The sensitivity of GenoType® MTBDRplus was 92.1% for RIF resistance and 97.4% for INH resistance, whereas the specificity was 100% for the two tested drugs. CONCLUSIONS: GenoType® MTBDRplus assay is a rapid, reliable and accurate tool for the detection of DR-TB in clinical specimens. Its routine use will be of a great interest to prevent the dissemination of DR-TB in the community.
Authors: Hind Karimi; Amal Oudghiri; Latifa En-Nanei; Mohammed El Mzibri; Amin Laglaoui; Imane Chaoui; Mohammed Abid Journal: Rev Inst Med Trop Sao Paulo Date: 2020-06-05 Impact factor: 1.846
Authors: Thales Alves Campelo; Paulo Rafael Cardoso de Sousa; Lucas de Lima Nogueira; Cristiane Cunha Frota; Paulo Renato Zuquim Antas Journal: Access Microbiol Date: 2021-08-02
Authors: Bugwesa Z Katale; Peter M Mbelele; Nsiande A Lema; Susana Campino; Stephen E Mshana; Mark M Rweyemamu; Jody E Phelan; Julius D Keyyu; Mtebe Majigo; Erasto V Mbugi; Hazel M Dockrell; Taane G Clark; Mecky I Matee; Stellah Mpagama Journal: BMC Genomics Date: 2020-02-21 Impact factor: 3.969